Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
about
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in ThailandThe spread, treatment, and prevention of HIV-1: evolution of a global pandemicVaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipientsHIV-1 prophylactic vaccines: state of the artRecent Advances in Lentiviral Vaccines for HIV-1 InfectionApproaches to preventative and therapeutic HIV vaccinesRecent update in HIV vaccine developmentImmune correlates of vaccine protection against HIV-1 acquisitionA Blueprint for HIV Vaccine DiscoveryA New Scientific Paradigm may be Needed to Finally Develop an HIV VaccineNonhuman primate models for HIV/AIDS vaccine developmentPoxvirus vectors as HIV/AIDS vaccines in humansHIV-1 neutralizing antibodies: understanding nature's pathwaysInduction of intestinal immunity by mucosal vaccines as a means of controlling HIV infectionVaccines for the 21st centuryThe future of HIV vaccine research and the role of the Global HIV Vaccine EnterpriseMicrobicides: a new hope for HIV preventionA global approach to HIV-1 vaccine developmentDesigning vaccines for the twenty-first century societyCatching HIV 'in the act' with 3D electron microscopyAn anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIVAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesCrystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 EnvStructure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1Structure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeAntiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory AntibodiesNew concepts in HIV-1 vaccine developmentRecent developments in clinical trial designs for HIV vaccine researchA next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodiesHIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectivenessPhylodynamics of HIV-1 from a phase III AIDS vaccine trial in Bangkok, ThailandHigh and persistent HIV seroincidence in men who have sex with men across 47 U.S. citiesHumoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin UsersGeneration and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern AfricaMonoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 bindingUse of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoproteinCo-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsA phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)Broad antibody mediated cross-neutralization and preclinical immunogenicity of new codon-optimized HIV-1 clade CRF02_AG and G primary isolatesIndirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects
P2860
Q21134955-527FF40B-3A86-47AC-8F68-77313F26E4A0Q22241890-2365C5E6-B9CC-41B9-92B6-75F3E299F2EAQ24602593-C7868930-39A9-491D-84E0-AAD8074BAB16Q26740042-0BCE3B0D-62C4-47BB-8C3F-9923B6771FEAQ26742169-469FF7D4-6AFA-49A6-A3EA-BA1C5DFB94CFQ26764851-EBE094C2-0F92-4C0C-8E2E-89867388560CQ26766628-6319FF2B-BDF1-43A5-B395-BB25FB85A96CQ26778573-CD27D59C-AD68-4D9D-A510-8FBD8B4E74ECQ26829865-FE353A9F-9D88-4DD9-90D0-0DB2D0E3DC10Q26830360-B4FF676E-E579-4CF6-B14F-B751BCA85A29Q26861148-D4BF2054-BD4F-495B-B222-4A1DC1676955Q26995078-B0AEFF5C-F6AB-4C9F-AAEF-56BE805904ABQ27000480-09C8A5AC-8078-469E-95E5-14A5031AC35DQ27001897-FBC3A85E-0F57-4DDA-BE8F-87D9267CD6B3Q27007529-85835FD1-B6E9-427A-B461-6B64871C34BCQ27010375-9EE39FC6-C6FC-4AAD-B81B-62D845753962Q27022779-A0590E10-34C5-40B4-BB9B-45428F4F44DBQ27024614-A48D6587-D03C-4D6D-9BA6-517AF4CBA738Q27025703-EB4DE698-BA00-4AD6-A943-8A5ADFDD6308Q27026806-BF79E051-33B3-4BC3-AC59-9192AF8DBBE1Q27349203-B52D78A0-518A-4A73-A685-AD61D3B46526Q27489000-A7978B98-01AB-4648-BA4B-05E00C1F8B62Q27644383-0F6CBD67-41E9-403B-AB4B-1CCF0D4F97BDQ27662155-929391F7-A6A2-4078-AC5E-6C2BAC262F00Q27675260-F0CD88B6-8AA9-4663-B38B-331B39AA0500Q28066335-F8514482-5D2A-4C25-920C-4CE91A66D8E3Q28067027-CF5A0007-B211-48CE-B1EF-301FF7B5A3CAQ28083514-BE5FD6DD-0DE2-4452-8FC5-2F39CF97F0FFQ28299280-DAC213B2-DD77-44B1-9261-C7B13F881823Q28474086-1B8642D0-52A0-4E9F-8DBB-66DD928215D6Q28477393-814C5D47-5A87-44AA-992A-2E8593B58374Q28482421-C84C6EB7-0F20-4BAE-B72B-C124FDD712D6Q28552355-E2F64020-A3AB-454B-8151-3D25476CF8F8Q28552786-DAC6C5A6-3499-4B2B-9E70-DBBD45DBCEB7Q28728517-CEC42FF8-6DA1-4FB2-A0A5-B5AEA794D184Q28730561-0AC7373A-1857-4FE7-BC72-DB186B80588DQ28732043-11DA649F-8502-48BD-A6B5-90525D13E2E1Q28741673-70DFC0D9-6519-4729-A70A-AE75A7FF99A7Q28741775-600F6F2B-EDF5-47D6-9522-E88E3CC2118EQ28743129-9B5A775E-6D77-483B-A2FE-B1FBF7CC5657
P2860
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Placebo-controlled phase 3 tri ...... ne to prevent HIV-1 infection.
@en
Placebo-controlled phase 3 tri ...... ne to prevent HIV-1 infection.
@nl
type
label
Placebo-controlled phase 3 tri ...... ne to prevent HIV-1 infection.
@en
Placebo-controlled phase 3 tri ...... ne to prevent HIV-1 infection.
@nl
prefLabel
Placebo-controlled phase 3 tri ...... ne to prevent HIV-1 infection.
@en
Placebo-controlled phase 3 tri ...... ne to prevent HIV-1 infection.
@nl
P2093
P356
P1476
Placebo-controlled phase 3 tri ...... ne to prevent HIV-1 infection.
@en
P2093
Clayton D Harro
Donald N Forthal
Franklyn N Judson
Michael F Para
Neil M Flynn
rgp120 HIV Vaccine Study Group
P304
P356
10.1086/428404
P407
P577
2005-01-27T00:00:00Z